A Phase II Evaluation of Vorinostat (SAHA NCI-Supplied Agent [NSC 701852 IND 71976]) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Trial Profile

A Phase II Evaluation of Vorinostat (SAHA NCI-Supplied Agent [NSC 701852 IND 71976]) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Aug 2008 The expected completion date for this trial is extended from Oct 2006 to 1 Jul 2008 as reported by ClinicalTrials.gov.
    • 06 Aug 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 30 Jul 2007 Status changed from suspended to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top